Harrow lowers profit guidance, holds sales target and moves up G-MELT filing

Harrow, Inc. said sales in the three months to September reached $99.3 million, the highest quarterly figure in its history, according to a stockholder letter dated 9 November 2026. The company credited its branded eye-care portfolio, naming VEVYE, IHEEZO, TRIESENCE and BYOOVIZ.

The headline growth did not carry through to the profit forecast. Harrow still expects full-year revenue of $350 million to $365 million, unchanged from before. It has cut its adjusted EBITDA expectation from a range of $80 million to $100 million to a floor of more than $40 million.

Harrow gave two reasons for the reduction. VEVYE brought in less net revenue per sale than planned in the first half, a pricing issue the company attributed to the gap between list and realised prices. It is also spending on research and development earlier than it had planned.

Part of that spending supports the pipeline. Harrow now intends to file a new drug application with the US Food and Drug Administration for G-MELT during 2026, ahead of the first-half 2027 timing it had previously given. Any FDA decision on whether to accept the filing would come after submission.

The company also expects a new coverage win for VEVYE that would extend access to more than 10 million commercial lives from 1 January. The information available does not name the payer or set out the terms.